The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’…
Articles by Forest Ray PhD
An experimental therapy that proved ineffective in treating HIV infections now has shown promising potential at preventing or limiting…
DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and…
High-dose AP01 (inhaled pirfenidone) largely prevented lung function decline and was safe and well-tolerated during the first 24 weeks…
Magnesium lithospermate B, a compound found in a traditional Chinese medicinal herb, eased several features of pulmonary fibrosis (PF)…
The U.S. Food and Drug Administration (FDA) granted fast track status to IM156, ImmunoMet Therapeutics’ treatment candidate for…
Often used in traditional Chinese medicine, a plant compound called salvianolic acid B, or SAB, has been found to…
Tyvaso (inhaled treprostinil) has been approved as the first treatment to improve exercise ability in people with pulmonary hypertension…
Exposure to fine particulate air pollutants, such as PM2.5 and nitric oxide (NO), raises the risk for acute flare-ups of…
CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases,…